CBD and multiple sclerosis

Multiple sclerosis (Latin: sclerosis multiplex, SM)- is a chronic disease of the nervous center in which it occurs multifocal damage to nerve tissue.

Multiple sclerosis was first published by Jean-Martin Charcot in 1868.

This disease most often affects young people between 20 and 40. age is a slight predominance of women.

In general, this disease affects nerve cells (neurons), glial immune cells of the brain( microglia) in which this occurs damage to the myelin envelope around nerve cells. Which inhibits the transmission of impulses along the nervous tract in the brain and spinal cord.

At the moment, it is believed that MS is an autoimmune disease in which the immune system fights the cells of its own body.

Some scientists see a large relationship between the occurrence of MS and cow's milk consumption.

Some researchers point to a significant deficiency of vitamin D during adolescence.

SM can cause many symptoms and syndromes of symptoms, these are most often motor disorders, sensory disorders, imbalances, visual disturbances, autonomic disorders, pain syndromes and psychiatric symptoms such as cognitive and mood disorders, and chronic fatigue.

Multiple sclerosis is one of the most common causes of disability in young people. 

clinical trials

The study was conducted on a 30-year-old patient, with An MS who smoked cigarettes for marijuana.

The effect was assessed by clinical evaluation of the electromyographic examination of the movement of leg bending and electromagnetic recording of shaking of hands.

 Cannabinoids have been found to have a strong beneficial effect on the patient.

clinical trials

During this study, 57 patients took part in this study of the hospital rehabilitation programme.

Cannabis extract capsules of 2.5 mg (THC) and 0.9 mg (CBD) were administered the second group to start a phase of 15 to 30mg THC increased daily by 5 mg .

During the hospital rehabilitation program, 57 patients took part in a prospective, randomised, double-blind, placebo-controlled cross-examination of cannabis extract capsules standardized at 2.5 mg tetrahydrocannabinol ( thc) and 0.9 mg cannabidiol (CBD) each. Patients in Group A started the escalation phase of the drug from 15 to a maximum of THC 30 mg by 5 mg per day.

 The subjects were tested for the frequency of cramps (Ashworth scale) and rivermead mobility rate.

Cannabis use was found to have been safe and had tolerated side effects while reducing the number of systolic seizures.

clinical trials

The study was conducted on 66 patients with multiple sclerosis.

Patients were given oral spray containing (THC and CBD) at a dose of THC 2.7mg and 2.5 CBD as supportive of analgesic therapy. And patients could give themselves up to a maximum of 48 doses within 24 hours.


The drug based on marijuana (THC and CBD) effectively reduces pain and sleep disorders in patients with central neuropathic pain associated with multiple sclerosis and is mostly well tolerated.

Published in the journal Neurology.

clinical trials

Leave a Reply

Your email address will not be published. Required fields are marked *